ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
99,011.84
-1.65%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Tyra Biosciences Inc (TYRA)

  7. Tyra Biosciences Inc (TYRA) 뉴스

TYRA

Tyra Biosciences (TYRA)

Tyra Biosciences Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:TYRA
일자시간출처헤드라인심볼기업
2025/01/3006:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2025/01/3006:05PR Newswire (US)Tyra Biosciences Announces Appointment of Adele Gulfo to Board of DirectorsNASDAQ:TYRATyra Biosciences Inc
2025/01/2308:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2025/01/2222:00PR Newswire (US)Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:TYRATyra Biosciences Inc
2025/01/1022:00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)NASDAQ:TYRATyra Biosciences Inc
2024/12/1007:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/12/0711:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/12/0711:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/12/0606:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/12/0309:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/2106:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/2011:31Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/11/1507:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/1406:05PR Newswire (US)Tyra Biosciences to Present at Upcoming Investor ConferencesNASDAQ:TYRATyra Biosciences Inc
2024/11/0806:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/11/0806:05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
2024/10/3105:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2906:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2820:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/2820:00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)NASDAQ:TYRATyra Biosciences Inc
2024/10/2521:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/2507:21PR Newswire (US)Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)NASDAQ:TYRATyra Biosciences Inc
2024/10/2405:05PR Newswire (US)Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETNASDAQ:TYRATyra Biosciences Inc
2024/10/2310:15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/10/2309:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2309:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/1905:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/1121:00PR Newswire (US)Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)NASDAQ:TYRATyra Biosciences Inc
2024/09/1905:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/09/1904:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
 검색 관련기사 보기:NASDAQ:TYRA

최근 히스토리

NASDAQ
GOOGL
Alphabet
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
FX
USDEUR
US Dollar vs Euro
USOTC
RHHBY
Roche (QX)
COIN
AVAXUSD
Avalanche
CCOM
US100
US Tech 100
NYSE
MRK
Merck
USOTC
ADDYY
Adidas (QX)
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
COIN
XRPUSD
Ripple
NYSE
DIS
Walt Disney
CCOM
US30
US 30
FX
USDJPY
US Dollar vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지